Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  BioSig Technologies Inc    

BIOSIG TECHNOLOGIES INC
My previous session
Most popular
  Report  
SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

BioSig Technologies to Present at Digital Medicine & Medtech Showcase at Biotech Showcase

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/28/2017 | 02:01pm CEST

Santa Monica, CA, Dec. 28, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it will present at the Digital Medicine & Medtech Showcase at Biotech Showcase(TM). The conference will be held January 8-10, 2018 at Parc 55 San Francisco – a Hilton Hotel.

Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc., will cover the Company overview as well as recent highlights during the presentation. To schedule a one-on-one meeting with BioSig, please contact Natasha Russkina, VP Business Development and Corporate Finance at nrusskina@biosigtech.com.

About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System.  The technology has been developed to address an unmet need in a large and growing market.

The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 

Contact:
Natasha Russkina
BioSig Technologies, Inc. 
VP Business Development & Corporate Finance 
nrusskina@biosigtech.com
+41 (0) 76 823 7527



Primary Logo


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOSIG TECHNOLOGIES INC
09/25BIOSIG TECHNOLOGIES : Retains Gilmartin Group for Investor Relations
AQ
09/19BioSig Technologies to Commence Trading on the Nasdaq
GL
09/11BioSig Technologies Issues Shareholder Letter
GL
09/11BIOSIG TECHNOLOGIES : Announces 1-for-2.5 Reverse Stock Split for Pending Uplist..
AQ
09/10BIOSIG TECHNOLOGIES, INC. : Material Modification to Rights of Security Holders,..
AQ
09/10BioSig Technologies, Inc. Announces 1-for-2.5 Reverse Stock Split for Pending..
GL
08/24BIOSIG TECHNOLOGIES, INC. : Other Events (form 8-K)
AQ
08/23BIOSIG TECHNOLOGIES, INC. : Unregistered Sale of Equity Securities (form 8-K)
AQ
08/22BioSig Technologies to Present at the MicroCap Leadership Summit
GL
08/21BIOSIG TECHNOLOGIES : Appoints Johnson & Johnson Veteran Amy Scott
AQ
More news
News from SeekingAlpha
09/10BIOSIG TECH REVERSE SPITS SHARES 1 : 2.5 
08/18YOUR DAILY PHARMA SCOOP : Catalyst Positive, JNJ Succeeds, Blue Chips Support Ti.. 
08/17BioSig Tech closes $6M equity offering 
08/15BioSig Tech up 5% on FDA approval for ECG data management system 
04/14DAILY INSIDER RATINGS ROUND UP 4/12/ : Conn, opk, bsgm 
Financials ($)
Sales 2018 -
EBIT 2018 -15,3 M
Net income 2018 -15,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 28,4x
Capitalization 71,0 M
Chart BIOSIG TECHNOLOGIES INC
Duration : Period :
BioSig Technologies Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 10,6 $
Spread / Average Target 128%
EPS Revisions
Managers
NameTitle
Kenneth L. Londoner Executive Chairman & Chief Executive Officer
Steven Chaussy Chief Financial Officer
Roy T. Tanaka Independent Director
Seth H. Z. Fischer Independent Director
Patrick Gallagher Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOSIG TECHNOLOGIES INC69.71%71
THERMO FISHER SCIENTIFIC21.87%94 516
DANAHER CORPORATION9.88%73 446
INTUITIVE SURGICAL42.29%61 755
BOSTON SCIENTIFIC CORPORATION46.95%52 551
ILLUMINA47.23%48 357